title: [Dynamic MRI of the lumbar spine for the evaluation of microcirculation during anti-angiogenetic therapy in patients with myelodysplastic syndromes].
abstract: OBJECTIVE
  Evaluation of MRI perfusion parameters of the lumbar spine in patients with myelodysplastic syndromes (MDS) to determine the vascularisation and anti-angiogenetic effects of thalidomide therapy.
  
  
  METHODS
  In 20 healthy normal persons and 28 MDS patients a dynamic contrast-enhanced MRI (d-MRI) of the lumbar spine was performed. After the initial d-MRI-investigation 24 of the 28 MDS patients received an anti-angiogenetic therapy with thalidomide. With an average of 4.2 months after the beginning of therapy a d-MRI-follow-up examination in 9 of these patients was performed. The amplitude and exchange-rate constant were calculated and a statistical comparison of these values between healthy persons and MDS patients as well as a correlation with the clinical course was executed.
  
  
  RESULTS
  Compared with the normal controls the MDS patients showed a higher amplitude (normal persons: 14.4 +/- 5.2, MDS: 24.8 +/- 8.1) and exchange-rate constant (normal persons: 0.124 +/- 0.042, MDS: 0.136 +/- 0.036). In 7 of 9 MDS patients undergoing thalidomide therapy a reduction of the amplitude and exchange rate constant values was evident in the d-MRI follow-up examinations. Clinically these patients showed a therapy response with complete or partial disease remission.
  
  
  CONCLUSIONS
  In MDS patients significantly higher d-MRI parameters can be demonstrated than in normal persons. Under anti-angiogenetic treatment these values decrease in case of a response to therapy. Thus, d-MRI seems suitable for the evaluation of anti-angiogenetic therapy effects.
authors.affiliation: Institut für Diagnostische Radiologie, Düsseldorf, Germany. scherera@uni-duesseldorf.de
authors.forename: A
authors.initials: A
authors.lastname: Scherer
authors.forename: C
authors.initials: C
authors.lastname: Strupp
authors.forename: H J
authors.initials: HJ
authors.lastname: Wittsack
authors.forename: V
authors.initials: V
authors.lastname: Engelbrecht
authors.forename: L W
authors.initials: LW
authors.lastname: Poll
authors.forename: U
authors.initials: U
authors.lastname: Reinwand
authors.forename: R
authors.initials: R
authors.lastname: Willers
authors.forename: U
authors.initials: U
authors.lastname: Germing
authors.forename: N
authors.initials: N
authors.lastname: Gattermann
authors.forename: R
authors.initials: R
authors.lastname: Haas
authors.forename: U
authors.initials: U
authors.lastname: Mödder
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D003627:Data Interpretation, Statistical; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008159:Lumbar Vertebrae; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide